Introduction
Blood is a precious resource obtained from voluntary, not remunerated donors [1] , and should be used to the greatest benefit of patients. In the last years, efforts have been undertaken in order to optimise the use of blood. Results of clinical trials published in recent years have shown that optimising the use of blood components, particularly red blood cell (RBC) concentrates, not only reduces the costs related to blood transfusion but also may influence positively the outcome of patients, or at least does not worsen it [2] [3] [4] [5] [6] . As a consequence, several guidelines for the use of RBCs have been developed by different societies and institutions [7] [8] [9] [10] [11] [12] [13] . Currently, further efforts to optimise patient care and use of blood components are ongoing under the concept of blood patient management [14] [15] [16] [17] .
In Switzerland, national guidelines for the transfusion of RBCs do not yet exist. But every institution transfusing blood components should implement a quality system in accordance with the current state of the art [18] . Guidelines for the use of blood components, as well as the documentation and the eval-
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Summary
Introduction:
Optimising the use of blood has become a core task of transfusion medicine. Because no general guidelines are available in Switzerland, we analysed the effects of the introduction of a guideline on red blood cell (RBC) transfusion for elective orthopaedic surgery. Methods: Prospective, multicentre, before-and-after study comparing the use of RBCs in adult elective hip or knee replacement before and after the implementation of a guideline in 10 Swiss hospitals, developed together with all participants. Results: We included 2,134 patients, 1,238 in 7 months before, 896 in 6 months after intervention. 57 (34 or 2.7% before, 23 or 2.6% after) were lost before follow-up visit. The mean number of transfused RBC units decreased from 0.5 to 0.4 per patient (0.1, 95% CI 0.08-0.2; p = 0.014), the proportion of transfused patients from 20.9% to 16.9% (4%, 95% C.I. 0.7-7.4%; p = 0.02), and the pre-transfusion haemoglobin from 82.6 to 78.2 g/l (4.4 g/l, 95% C. I. 2.15-6.62 g/l, p < 0.001). We did not observe any statistically significant changes in inhospital mortality (0.4% vs. 0%) and morbidity (4.1% vs. 4.0%), median hospital length of stay (9 vs. 9 days), follow-up mortality (0.4% vs. 0.2%) and follow-up morbidity (6.9% vs. 6.0%). use of RBC concentrates. We targeted a multicentre approach including different kinds of hospitals for elective orthopaedic surgery and a single university hospital for cardiovascular surgery. In this article we describe principles, methods and results of the multicentre study in hip and knee prosthesis in the hope, that this will inspire others to take similar initiatives, possibly as a first step towards development of a complete patient blood management programme. Meanwhile, since the performance of the project, the number of delivered RBC concentrates has dropped by about 10% and even by about 15% on a per inhabitant basis in Switzerland [19] , and this reduction is still ongoing. We are not able to state if the results are a consequence of this first and until now unique initiative in Switzerland trying to optimise the use of blood on a broad base, but during and after this project the use of blood compouation of their use, should be part of this quality system. However, implementing and teaching a guideline as well as evaluating its effect is a major challenge for hospitals being more and more confronted with limited financial and personal resources. Furthermore, blood transfusion is in fact a complex but at the same time a very safe process that represents only a small proportion of the hospital costs and activities. Thus, hospitals usually depend on any kind of significant support/ funding for their efforts to achieve the implementation of guidelines. With this purpose, 5 years ago our group applied for a grant from the Swiss Red Cross Humanitarian Foundation (SRC-HF), which amongst others supports research and development in the field of transfusion medicine. We planned to develop and introduce guidelines within Swiss hospitals interested to implement them and to evaluate their effect on the Fontana/de la Cuadra/Müller/Schmid/Perler/ Luginbühl/Mansouri Taleghani comes were the differences between the proportion of transfused patients, the pre-transfusion haemoglobin values and the patient outcomes at the end of their hospitalisation and at the first consultation at least 30 days after surgery. The patient outcomes comprised mortality and cumulative complication rate, including cardiovascular events, bleedings, and infections (CTCAE grade 3 or higher [20] ).
Selection and Recruitment of Centres
We sent a letter to all Swiss hospitals known to include an orthopaedic unit, inviting them to participate in the study on a voluntary basis. Ten hospitals accepted to participate and completed the study. The 10 hospitals performed about 7% of the elective hip and knee replacements in Switzerland during the study period. They were distributed in the 3 Cantons of Bern (central-western part of Switzerland, 5 hospitals), St. Gallen (eastern part of Switzerland, 3 hospitals), and Ticino (southern part of Switzerland, 2 hospitals). They comprised 1 university hospital, 3 public cantonal hospitals, 4 public regional hospitals and 2 private regional hospitals.
Inclusion and Exclusion Criteria
All adult (at least 18 years of age) prospective patients undergoing elective hip or knee replacement during the study period were included, independently from comorbidities or risk factors. Excluded were nonelective interventions, patients with concomitant surgical procedures, patients younger than 18 years, patients refusing transfusions or patients for whom no adequate RBCs were available in the regional stock because of multiple RBC antibodies or rare blood groups. nents was repeatedly debated throughout the country, and several clinics implemented this or similar guidelines. Therefore, we hope to have given a valuable contribution to the current positive development.
Material and Methods
Study Design and Participating Hospitals
We designed the protocol as a prospective, multicentre, before-andafter cohort study in orthopaedic surgery, including all prospective patients planned for elective hip or knee replacement during the study period in the hospitals accepting to participate. During the first 6 months (August 2007 to January 2008), we monitored the RBC use and the patient outcomes (phase 1 of the protocol). At the end of phase 1, a RBC transfusion guideline, jointly developed with the participating hospitals, was introduced and implemented. Because the development process of the guideline took 1 month longer than planned, we prolonged phase 1 to 7 months (until February 2008). Transfusion data were continuously monitored until completion of a subsequent post-interventional period of 6 months (phase 2 of the protocol, March to August 2008). Because the aims of the project were part of the development of a mandatory quality system, in particular to implement measures for optimal blood use [18] , the local Ethical Committee confirmed that no formal approval of the protocol was needed.
The primary outcome was the difference in the number of RBC concentrates per surgical intervention between phase 1 and 2. Secondary out- 
Results
Out of 2,144 surgical interventions recorded during the study period, 2,134 could be evaluated for transfusion of RBC concentrates, haemoglobin trigger and in-hospital morbidity; data on surgery, transfusion or haemoglobin values were partially missing in 10 cases. 57 (2.7%) patients were lost during follow-up (34 in phase 1 (2.7%), 23 in phase 2 (2.6%)), in all cases because no medical reports of the follow-up visits were sent back to the study office. Consequently, 2,077 patients were evaluable at the last follow-up >30 days after surgery.
Basic characteristics of the patients and of the surgical procedures are reported in table 2. No differences were observed between phase 1 and 2, except for a higher number of prosthesis replacements and slightly higher preoperative haemoglobin values in phase 1. The distribution of surgical procedures between the hospitals is summarised in table 3; only minimal differences in the distribution between phase 1 and 2 were observed.
After the introduction of the guideline, we observed a decrease of the mean number of RBC transfusions from 0.5 to 0.4 units per patient (p = 0.014), which corresponds to a 20% reduction of the transfused RBC concentrates. Less patients received any transfusion of RBCs, and the haemoglobin level prior to transfusion was lower in phase 2 (table 4). In order to test whether differences in baseline variables do have an influence on the results, the analyses for the primary outcome and for the proportion of transfused patients were repeated after
Development of the Guideline
In order to improve the compliance, we developed a simple, evidencebased guideline together with the anaesthetists and/or orthopaedic surgeons responsible for the interventions in the participating hospitals ( fig.  1 ). For this purpose, the authors of this paper reviewed the literature for available guidelines (considered guidelines are listed in table 1), checked their compatibility with the published controlled clinical trials at this time (considered studies see table 1) and distributed a draft to all responsible persons of the participating hospitals. To avoid a bias during phase 1, the draft guideline was discussed with all participants, finalised and trained locally in the hospitals to as many medical doctors as possible only at the end of the phase 1. The finalised guideline was subsequently implemented in the standard procedures of the participating hospitals. One copy was put in the medical records of every patient included in phase 2 of the study, and pocket leaflets were distributed to the medical doctors. In order to properly complete this process, we had to prolong phase 1 of the study by 1 month (i.e., 7 instead of 6 months).
Data Collection and Statistical Analysis
We collected data on patients' characteristics, surgical interventions, haemoglobin values, transfusions and complications during hospitalisation and until the last follow-up. In order to control the patient groups for general condition and comorbidities, we registered the American Society of Anaesthesiology (ASA) status. Two study nurses, specifically trained for the project, prospectively collected all the data from the hospital clinical records and from the reports of the follow-up visits, and entered them in a web-based electronic database of the Institute for Evaluative Research in Orthopaedic Surgery of the University of Bern which also performed the statistical analyses using SAS 9.1 (SAS Institute Inc., Cary, NC, USA).
The primary endpoint, the comparison between phase 1 and phase 2 regarding the mean numbers of RBC concentrates transfused per patient [14] [15] [16] [17] . Projects aimed to achieve this goal are time-consuming, and under the current financial and performance pressure it is often difficult to find the resources needed. Our experience suggests that improvements can be achieved by a small group of persons leading and coordinating the activities of the major players in transfusion medicine. Key factors that may have contributed to the success of the guideline are in our opinion its simplicity, the lack of requirement for major changes, the concerted development in collaboration with the local opinion leaders, its wide distribution among the staffs and the development of a sense of ownership on the guideline and on the results achieved. Effectively, because the guideline was based on the current literature applicable for several patient categories and no negative effects after its introduction could be observed (see below), we could make it immediately available for all participating institutions after the study. The participating university hospital also applied the guideline for other non-orthopaedic wards like cardiovascular surgery. In this way we achieved our goal to implement guidelines as part of a quality management system making the first step towards the concept of patient blood management in the hospitals. Our intervention also showed a significant effect in reducing the RBC use and the proportion of transfused patients, among others by reducing the mean haemoglobin level prior to transfusion. In this context, the project may have some limitations. First, confounding factors may have resulted in a lower transfusion need irrespective of the guideline. But this effect was still observed after adjustment for differences between the two phases, probably because in phase 2 the patients actually received fewer transfusions despite lower preoperative haemoglobin values. Furthermore, no hospital reported other changes in their surgical or other perioperative procedures, which could also have influenced the results. Second, the observed change may be related to a concomitant, general reduction of transfused RBC concentrates in Switzerland during the same time interval, independent of the initiative of our project. But this is not the case, as the RBC use in Switzerland actually increased by 1.6% between 2007 and 2008 [19] . Third, the effect of being under study may already adjustment for variables found to have an influence on the transfusion need by logistic regression. These comprise age (p < 0.001), preoperative haemoglobin (p < 0.001), % of prosthesis replacement (p < 0.001) and type of anaesthesia (p = 0.037). Additionally to the raw results in table 4, adjusted differences in RBC use or odds ratios for transfusion probability are reported in table 5. The adjusted data confirmed the findings of the unadjusted raw data.
The variability between hospitals decreased in the phase 2 for both the number of transfused RBC units per patient and the proportion of transfused patients. The range of transfused RBC units per patient decreased from 0.11-1.16 in phase 1 to 0.14-0.69 in phase 2 (p < 0.001). The range of the proportion of transfused patients decreased from 4.6-43.7% in phase 1 to 6.9-28.3% in phase 2 (p < 0.001). The inter-hospital range of the pre-transfusion haemoglobin values in phase 1 was 76.9-88.9 and in phase 2 68.5-81.2 (not significant).
We did not observe any differences in length of hospital stay, mortality and cumulative complication rates between phase 1 and 2. The mean time point of the last follow-up was 3 days earlier in phase 2. The results are outlined in table 6.
Discussion
In the last years, efforts to optimise the use of blood have been undertaken in several countries, transfusion guidelines for RBC concentrated have been published [7] [8] [9] [10] [11] [12] [13] , and a further optimisation is ongoing under the concept of patient higher morbidity. Second, 57 patients were lost from followup. Their number was low, the reason for the missing data for all patients the same, and the patient number was nearly balanced between phase 1 and 2. Therefore, it is unlikely that an additional bias may have influenced the results. But obviously the validity of the results should be demonstrated in a randomised trial.
In conclusion, a simple transfusion guideline ( fig. 1 ) could be introduced in 10 Swiss hospitals. It was broadly accepted and quickly implemented; it reduced and standardised the use of RBCs by decreasing the haemoglobin transfusion trigger without negative effects on the patient outcome. Furthermore, it complied successfully with the legal demand of introducing quality systems in the hospitals. Since the end of this project, the necessity to implement guidelines and other instruments optimising the use of blood has been repeatedly debated in Switzerland: the use of RBC concentrates per 1,000 inhabitants has dropped by about 15% so far (end of 2013) [19] . Furthermore, several hospitals are now evaluating blood patient management programmes, and additional efforts to optimise the use of blood are still ongoing. With the presented project we hope to have given a valuable contribution to the current positive development and to inspire others to take similar initiatives.
have reduced the RBC need in phase 1. In order to avoid this effect, we restricted information about the project to the single responsible persons in the hospitals, and the staffs were informed only at the moment of the training and implementation of the guideline.
The observed effect was lower than that observed in a similar former study performed in a single centre in Switzerland [21] . The RBC use and its variability in Switzerland seem also to be relatively low when compared to other countries [22, 23] . This suggests that the potential for improvement in RBC use may be limited, at least for elective orthopaedic surgery in Switzerland. Alternatively, the institutions accepting to participate could have been those where physicians have been already aware of good transfusion practices and therefore beforehand have applied certain transfusion rules. Our result from a parallel survey at a university clinic showed a rate of transfused patients of 67.9% in elective patients undergoing aortic aneurysm, coronary artery bypass and hearth valve surgery [24] , and the comparison with the literature suggests that further improvement may be achieved also in other indications than orthopaedic surgery [25] . Furthermore, the observed preoperative haemoglobin values were relatively close to the lower norm value for men [26, 27] , who represented 45% of the patients in our collective. Thus, we suggest that developing towards a complete patient blood management programme by correcting preoperative anaemia should further reduce the transfusion need.
There is now evidence from randomised trials that a reduction of the haemoglobin transfusion trigger does not influence negatively the morbidity or mortality [2] [3] [4] [5] [6] . Consistently, we found no differences between phase 1 and 2, neither with regard to the in-hospital complications nor during the time until the follow-up performed >30 days after surgery. However, two elements have to be considered in the interpretation of the follow-up results. First, the mean time point of the last follow-up was 3 days earlier in phase 2 than in phase 1 (49 vs. 52 days, see table 6). This may cause an underestimation of the proportion of adverse events in phase 2. However, because of the moderate extent of the difference, the elapsed time interval since the intervention and the trend towards a lower number of events in phase 2, it seems at least unlikely that the introduction of our guideline may have caused a
